PPM1D mutations in circulating white blood cells and the risk for ovarian cancer

Journal of the National Cancer Institute

Volumn 106, Issue 1, 2014, Pages

  Akbari, Mohammad R ^a   Lepage, Pierre ^b   Rosen, Barry ^c   McLaughlin, John ^a   Risch, Harvey ^d   Minden, Mark ^c   Narod, Steven A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; PROTEIN PHOSPHATASE MAGNESIUM DEPENDENT 1; UNCLASSIFIED DRUG; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2C;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; GENE FREQUENCY; GENE MUTATION; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MIDDLE AGED; MOSAICISM; OVARY CANCER; PRIORITY JOURNAL; BREAST TUMOR; CANADA; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; INCIDENCE; METABOLISM; MORTALITY; MUTATION; OVARY TUMOR; PROPORTIONAL HAZARDS MODEL; RISK; RISK ASSESSMENT; RISK FACTOR;

AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CANADA; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; INCIDENCE; LEUKOCYTES; MIDDLE AGED; MUTATION; ODDS RATIO; OVARIAN NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASES; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS;

EID: 84892631703     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt323     Document Type: Article

References (16)

1. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian cancer, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. PNAS. 2011;108(44):18032-18037.
2. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121(2):35-37.
3. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008;122(9):2017-2022.
4. Finch A, Beiner M, Lubinski J, et al. Salpingooophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296(2):185-192.
5. Ruark E, Snape K, Humburg P, et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013;493(7432):406- 410.
6. McLaughlin JR, Rosen B, Moody J, et al. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst. 2013;105(2):141-148.
7. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-1760.
8. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303.
9. Fiscella M, Zhang H, Fan S, et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA. 1997;94(12):6048-6053.
10. Takekawa M, Adachi M, Nakahata A, et al. p53-Inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J. 2000;19(23):6517-6526.
11. Proia DA, Nannenga BW, Donehower LA, Weigel NL. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. J Biol Chem. 2006;281(11):7089-7101.
12. Bulavin DV, Demidov ON, Saito S, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet. 2002;31(2):210-215.
13. Hirasawa A, Saito-Ohara F, Inoue J, et al. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res. 2003;9(6):1995-2004.
14. Festa F, Gomes LR, Rodrigues L, et al. PPM1D/Wip1 expression is increased in prostate carcinoma with high Gleason score and is regulated by the androgen mitogen (abstract). Proc Amer Assoc Cancer Res. 2006;47:abstract 5032.
15. Chuman Y, Kurihashi W, Mizukami Y, Nashimoto T, Yagi H, Sakaguchi K. PPM1D430, a novel alternative splicing variant of the human PPM1D, can dephosphorylate p53 and exhibits specific tissue expression. J Biochem. 2009;145(1):1-12.
16. Macurek L, Benada J, Müllers E, et al. Downregulation of Wip1 phosphatase modulates the cellular threshold of DNA damage signaling in mitosis. Cell Cycle. 2013;12(2): 251-262.